Bayer has begun conversations with the legal representation of its workers in Spain to initiate an Employment Regulation File (ERE) that will affect 135 positions in its pharmaceutical division, as reported by the company in a statement and collected by Europa Press.
Compensations for glyphosate and amortizations of the agricultural business make Bayer lose more than 10,000 million in 2020
Further
This measure, which will affect almost 6% of the total workforce in Spain made up of more than 2,400 professionals, “is a consequence of the market situation in the country, marked by the difficulties of access to new drugs, and the maturity of some of the company’s key brands,” the multinational has declared.
Given this context, Bayer has decided to focus its commercial promotion action on new launches with growth potential, thus reducing efforts on products that are in the final phase of their life cycle. Likewise, the company seeks to adjust its structures and modify the organizational model of commercial promotion and support of various business units.
In addition, Bayer has assured that it maintains its commitment to all agents in the health ecosystem to continue improving the quality of life of patients and contributing to the sustainability of the health system. The company also wanted to emphasize that it will carry out this process “in a socially responsible manner and will report, within the legal framework, transparently and regularly on any progress.”
13 layoffs at the Asturias plant
Bayer has informed the Government of the Principality of Asturias that the announcement to apply an employment regulation file (ERE) that affects 13 people at the Lada plant in Asturias does not put the future or the investments announced by the company at risk.
According to the information provided by the pharmaceutical company to the Ministry of Ecological Transition, Industry and Economic Development of the Principality, these measures “are of a temporary nature and derive from incidents in the Spanish market for pharmaceutical products.”
The multinational currently produces four active ingredients in Asturias, including acetylsalicylic acid, which serves as the basis for the manufacture of aspirin. Bayer, which has more than 140 workers in the region, has informed the Government of Asturias that this decision does not compromise the investments announced in its center in the autonomous community.
For its part, the Government of the Principality trusts “that the period of negotiation of the file with the workers’ representation will allow us to find the best solutions for the affected people.”
